WO1996024587A1 - Compose favorisant la liberation de l'hormone de croissance - Google Patents

Compose favorisant la liberation de l'hormone de croissance Download PDF

Info

Publication number
WO1996024587A1
WO1996024587A1 PCT/DK1996/000059 DK9600059W WO9624587A1 WO 1996024587 A1 WO1996024587 A1 WO 1996024587A1 DK 9600059 W DK9600059 W DK 9600059W WO 9624587 A1 WO9624587 A1 WO 9624587A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
aryl
independently
general formula
pharmaceutically acceptable
Prior art date
Application number
PCT/DK1996/000059
Other languages
English (en)
Inventor
Michael Ankersen
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Priority to AU45346/96A priority Critical patent/AU4534696A/en
Publication of WO1996024587A1 publication Critical patent/WO1996024587A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/08—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms with acylated ring nitrogen atom

Definitions

  • the present invention relates to novel compounds, compositions containing them, and their use for treating medical disorders resulting from a deficiency in growth hormone.
  • Growth hormone is a hormone which stimulates growth of all tissues capable of growing.
  • growth hormone is known to have a number of effects on metabolic processes, e.g., stimulation of protein synthesis and free fatty acid mobilization and to cause a switch in energy metabolism from carbohydrate to fatty acid metabolism.
  • Deficiency in growth hormone can result in a number of severe medical disorders, e.g. , dwarfism.
  • Growth hormone is released from the pituitary. The release is under tight control of a number of hormones and neurotransmitters either directly or indirectly.
  • Growth hormone release can be stimulated by growth hormone releasing hormone (GHRH) and inhibited by somatostatin.
  • GHRH growth hormone releasing hormone
  • the hormones are released from the hypothalamus but their action is mediated primarily via specific receptors located in the pituitary.
  • Other compounds which stimulate the release of growth hormone from the pituitary have also been described.
  • glucagon glucagon
  • vasopressin PACAP (pituitary adenylyl cyclase activating peptide)
  • GHRP growth hormone releasing peptide release endogenous growth hormone either by a direct effect on the pituitary or by affecting the release of GHRH and/or somatostatin from the hypothalamus.
  • growth hormone makes anything but parenteral administration non-viable.
  • other directly acting natural secretagogues e.g., GHRH and PACAP, are longer polypeptides for which reason oral administration of them is not viable.
  • composition of growth hormone releasing compounds is important for their growth hormone releasing potency as well as their bioavailability. It is therefore the object of the present invention to provide compounds with growth hormone releasing properties which have improved properties relative to known peptides of this type.
  • the present invention relates to a compound of general formula I I
  • n and p are independently 0, 1 or 2
  • R 1 is hydrogen, aryl or C 1-6 -alkyl optionally substituted with halogen, amino, hydroxy or aryl;
  • A is aryl or C 1-6 -alkyl optionally substituted with aryl, -CONR 3 R 4 or
  • R 3 , R 4 , R 5 , and R 6 independently are hydrogen, aryl or C 1-6 -alkyl optionally substituted with halogen, amino, hydroxy or aryl,
  • R 3 , R 4 , R 5 or R 6 is an aryl or C 1-6 -alkyl substituted with aryl;
  • R 7 , R 6 , R 5 and R 10 independently are hydrogen or C 1-6 - alkyl optionally substituted with halogen, amino, hydroxy or aryl, R 7 and R 8 , R 9 and R 10 , R 7 and R 9 or R 8 , and R 10 optionally forming -(CH 2 ) i -U-(CH 2 ) j -, wherein i and j are independently 1, 2 or 3,
  • U is -O-, -S- or a valence bond
  • o and r are independently 0, 1, 2, 3 or 4,
  • s 0 or 1
  • r + s + o is 2, 3 or 4; or a pharmaceutically acceptable salt thereof. It is believed that compounds of formula I exhibit an improved bioavailability because they contain no amide bonds susceptible to cleavage by proteolytic enzymes. The increased resistance to proteolytic degradation combined with the reduced size of the compounds of the invention in comparison with known growth hormone releasing compounds is expected to improve their bioavailability compared to that of the compounds suggested in the prior literature.
  • the C 1-6 -alkyl groups specified above are intended to include those alkyl groups of the designated length in either a linear or branched or cyclic configuration.
  • linear alkyl are methyl, ethyl, propyl, butyl, pentyl, and hexyl.
  • branched alkyl are isopropyl, sec-butyl, tert-butyl, isopentyl, and isohexyl.
  • Examples of cyclic alkyl are cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
  • C 1-6 -alkyl groups are the C 1-3 -alkyl groups.
  • Preferred C 1-3 -alkyl groups are methyl, ethyl, isopropyl, and cyclopropyl.
  • the C 1-6 -alkoxy groups specified above are intended to include those alkoxy groups of the designated length in either a linear or branched or cyclic configuration.
  • linear alkyloxy are methoxy, ethoxy, propoxy, butoxy, pentoxy, and hexoxy.
  • branched alkoxy are isopropoxy, sec-butoxy, tert-butoxy, isopentoxy, and isohexoxy.
  • cyclic alkoxy are cyclopropyloxy, cyclobutyloxy, cyclopentyloxy and cyclohexyloxy.
  • C 1-6 -alkoxy groups are the C 1-3 -alkoxy groups.
  • Preferred C 1-3 -alkoxy groups are methoxy, ethoxy, isopropoxy, and cyclopropyloxy.
  • the C 1-6 -alkylamino groups specified above are intended to include those alkylamino groups of the designated length in either a linear or branched or cyclic configuration.
  • linear alkylamino are methylamino, ethylamino, propylamino, butylamino, pentylamino, and hexylamino.
  • branched alkylamino are isopropylamino, sec-butylamino, tert-butylamino, isopentylamino, and isohexylamino.
  • Examples of cyclic alkylamino are cyclopropylamino, cyclobutylamino, cyclopentylamino and cyclohexylamino.
  • C 1-6 -alkylamino groups are the C 1-3 -alkylamino groups.
  • Preferred C 1-3 -alkylamino groups are methylamino, ethylamino, isopropylamino, and cyclopropylamino.
  • aryl is intended to include aromatic rings, such as carbocyclic and heterocyclic aromatic rings selected from the group consisting of phenyl, naphthyl, pyridyl, 1-H-tetrazol-5-yl, thiazolyl, imidazolyl, indolyl, pyrimidinyl, thiadiazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiopheneyl, quinolinyl, pyrazinyl, or isothiazolyl, optionally substituted by one or more C 1-6 -alkyl, C 1-6 -alkoxy, halogen, amino or aryl.
  • aromatic rings such as carbocyclic and heterocyclic aromatic rings selected from the group consisting of phenyl, naphthyl, pyridyl, 1-H-tetrazol-5-yl, thiazolyl, imidazolyl, indolyl, pyrimidinyl,
  • Aryl is preferably phenyl, thienyl, imidazolyl, pyridyl, indolyl, quinoline or naphthyl optionally substituted with halogen, carboxamido, tetrazolyl, oxadiozolyl, thiadiazolyl, amino, hydroxy, C 1-6 -alkyl or C 1-6 -alkoxy.
  • halogen is intended to include Cl, F, Br and I.
  • the compounds of the present invention may have one or more asymmetric centres and stereoisomers in the form of separated, pure or partially purified stereoisomers or racemic mixtures thereof are intended to be included in the scope of the invention.
  • Compounds of formula I may be prepared from natural or non-natural amino acid residues as shown in one of the following reaction schemes.
  • the non-natural amino acid residues may be prepared according to methods known to those skilled in the art.
  • Compounds of formula I may be prepared as shown in reaction scheme I starting with quinoline l and a Grignard reagent such as arylmagnesium bromide, which may be prepared from the corresponding bromide after methods known for those skilled in the art, or an organolithium compound such as phenyllithium in an appropriate solvent such as THF.
  • the addition product may then be reduced by a reducing agent such as hydrogen over platinoxide in methanol or sodium in methanol to give the tetrahydroquinoline product 2.
  • the desired compound 3 may be prepared by reaction between 2 and e.g. an isothiocyanate (D-NCS) in the presence of a base such as lithium diidopropylamide in an appropriate solvent such as THF.
  • D-NCS isothiocyanate
  • Compounds of formula I may be prepared by the method shown in reaction scheme II starting with an amino acid ester of the type 4, which may either be commercially available or prepared by methods known to those skilled in the art e.g. R. Nagata et al. (J. Med. Chem. 1994, 37, 3956-3968) and a compound of the type D-NCS, e.g. isothiocyanate or isocyanate in the presence of a base such as lithium diisopropylamide in an appropriate solvent such as THF.
  • the carboxylic acid 6 may be prepared from the ester 5 by methods known by those skilled in the art, e.g. with lithium hydroxide in an appropriate solvent such as dioxane/water.
  • the desired compound 7 may be prepared from 6 and an amidated aminoacid by methods known by those skilled in the art, e.g. peptide coupling methodologies described in the art (e.g. DCC in DMF) .
  • Functional groups in intermediates in reaction scheme II may be protected and deprotected using a strategy known in the art and described by e.g. T.W. Greene (Protective Groups in Organic Synthesis, 2nd Ed., John Wiley and Sons 1991).
  • Compound 7 is a compound of formula I.
  • Pharmaceutically acceptable acid addition salts of compounds of formula I include those prepared by reacting the compound with an inorganic or organic acid such as hydrochloric, hydrobromic, sulfuric, acetic, phosphoric, lactic, maleic, phthalic, citric, glutaric, gluconic, methanesulfonic, salicylic, succinic, tartaric, toluenesulfonic, trifluoracetic, sulfamic or fumaric acid.
  • an inorganic or organic acid such as hydrochloric, hydrobromic, sulfuric, acetic, phosphoric, lactic, maleic, phthalic, citric, glutaric, gluconic, methanesulfonic, salicylic, succinic, tartaric, toluenesulfonic, trifluoracetic, sulfamic or fumaric acid.
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising, as an active ingredient, a compound of the general formula I or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier or diluent.
  • Pharmaceutical compositions containing a compound of the present invention may be prepared by conventional techniques, e.g. as described in Remington's Pharmaceutical Sciences, 1985. The compositions may appear in conventional forms, for example capsules, tablets, aerosols, solutions, suspensions or topical applications.
  • the pharmaceutical carrier or diluent employed may be a conventional solid or liquid carrier.
  • solid carriers are lactose, terra alba, sucrose, cyclodextrin, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid or lower alkyl ethers of cellulose.
  • liquid carriers are syrup, peanut oil, olive oil, phospholipids, fatty acids, fatty acid amines, polyoxyethylene or water.
  • the carrier or diluent may include any sustained release material known in the art, such as glyceryl monostearate or glyceryl distearate, alone or mixed with a wax.
  • the preparation may be tabletted, placed in a hard gelatin capsule in powder or pellet form or it can be in the form of a troche or lozenge.
  • the amount of solid carrier will vary widely but will usually be from about 25 mg to about 1 g.
  • the preparation may be in the form of a syrup, emulsion, soft gelatin capsule or sterile injectable liquid such as an aqueous or non-aqueous liquid suspension or solution.
  • a typical tablet which may be prepared by conventional tabletting techniques may contain: Core:
  • the preparation may contain a compound of formula I dissolved or suspended in a liquid carrier, in particular an aqueous carrier, for aerosol application.
  • a liquid carrier in particular an aqueous carrier
  • the carrier may contain additives such as solubilizing agents, e.g. propylene glycol, surfactants, absorption enhancers such as lecithin (phosphatidylcholine) or cyclodextrin, or preservatives such as parabenes.
  • the compounds of the present invention are dispensed in unit dosage form comprising 50-200 mg of active ingredient together with a pharmaceutically acceptable carrier per unit dosage.
  • the dosage of the compounds according to this invention is suitably 0.1-500 mg/day, e.g. from about 5 to about 50 mg, such as about 10 mg per dose, when administered to patients, e.g. humans, as a drug.
  • the present invention relates to a pharmaceutical composition for stimulating the release of growth hormone from the pituitary, the composition comprising, as an active ingredient, a compound of the general formula I or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier or diluent.
  • the present invention relates to a method of stimulating the release of growth hormone from the pituitary, the method comprising administering to a subject in need thereof an effective amount of a compound of the general formula I or a pharmaceutically acceptable salt thereof.
  • the present invention relates to the use of a compound of the general formula I or a pharmaceutically acceptable salt thereof for the preparation of a medicament for stimulating the release of growth hormone from the pituitary.
  • growth hormone may be summarized as follows: stimulation of growth hormone release in the elderly; prevention of catabolic side effects of glucocorticoids, prevention and treatment of osteoporosis, stimulation of the immune system, acceleration of wound healing, accelerating bone fracture repair, treatment of growth retardation, treating renal failure or insufficiency resulting from growth retardation, treatment of physiological short stature including growth hormone deficient children and short stature associated with chronic illness, treatment of obesity and growth retardation associated with obesity, treating growth retardation associated with the Prader-Willi syndrome and Turner's syndrome; accelerating the recovery and reducing hospitalization of burn patients; treatment of intrauterine growth retardation, skeletal dysplasia, hypercortisolism and Cushing's syndrome; induction of pulsatile growth hormone release; replacement of growth hormone in stressed patients, treatment of osteochondrodysplasias, Noonan's syndrome, schizophrenia, depressions, Alzheimer's disease, delayed wound healing and psychosocial deprivation, treatment of pulmonary dysfunction and ventilator dependency, attenuation of protein
  • dosage levels between 0.0001 and 100 mg/kg body weight daily are administered to patients and animals to obtain effective release of endogenous growth hormone.
  • dosage forms suitable for oral, nasal, pulmonal or transdermal administration comprise from about 0.0001 mg to about 100 mg, preferably from about 0.001 mg to about 50 mg of the compounds of formula I admixed with a pharmaceutically acceptable carrier or diluent.
  • the compounds of formula I may be administered in pharmaceutically acceptable acid addition salt form or, where appropriate, as a alkali metal or alkaline earth metal or lower alkylammonium salt. Such salt forms are believed to exhibit approximately the same order of activity as the free base forms.
  • the pharmaceutical composition of the invention may comprise a compound of formula I combined with one or more compounds exhibiting a different activity, e.g., an antibiotic or other pharmacologically active material.
  • the route of administration may be any route which effectively transports the active compound to the appropriate or desired site of action, such as oral, nasal, pulmonary, transdermal or parenteral, the oral route being preferred.
  • routes of administration may be any route which effectively transports the active compound to the appropriate or desired site of action, such as oral, nasal, pulmonary, transdermal or parenteral, the oral route being preferred.
  • they may be useful in vitro tools for investigating the regulation of growth hormone release.
  • Compounds of formula I may also be useful in vivo tools for evaluating the growth hormone releasing capability of the pituitary. For example, serum samples taken before and after administration of these compounds to humans can be assayed for growth hormone. Comparison of the growth hormone in each serum sample would directly determine the ability of the patients pituitary to release growth hormone. Compounds of formula I may be administered to commercially important animals to increase their rate and extent of growth, and to increase milk production.
  • growth hormone secretagogue compounds of formula I is in combination with other secretagogues such as GHRP (2 or 6), GHRH and its analogues, growth hormone and its analogues or somatomedins including IGF-1 and IGF-2.
  • Compounds of formula I may be evaluated in vitro for their efficacy and potency to release growth hormone in rat pituitary primary cultures.
  • rat pituitary cells The isolation of rat pituitary cells is a modification of O. Sartor et al., Endocrinology 116, 1985, pp. 952-957.
  • Male albino Sprague-Dawley rats 250 +/- 25 grams were purchased from M ⁇ llegaard, Lille Skensved, Denmark. The rats were housed in group cages (four animals/cage) and placed in rooms with 12 hour light cycle. The room temperature varied from 19-24oC and the humidity from 30 - 60%.
  • the rats were decapitated and the pituitaries dissected.
  • the neurointermediate lobes were removed and the remaining tissue was immediately placed in icecold isolation buffer (Gey's medium (Gibco 041-04030) supplemented with 0.25% D-glucose, 2% non-essential amino acids (Gibco 043-01140) and 1% bovine serum albumine (BSA) (Sigma A-4503)).
  • the tissue was cut into small pieces and transferred to isolation buffer supplemented with 3.8 mg/ml of trypsin (Worthington #3707 TRL-3) and 330 mg/ml of DNase (Sigma D-4527).
  • This mixture was incubated at 70 rotations/min for 35 min at 37oC in a 95/5% atmosphere of O 2 /CO 2 .
  • the tissue was then washed three times in the above buffer. Using a standard pasteur pipet, the tissue was then aspirated into single cells. After dispersion, cells were filtered through a nylon filter (160 mm) to remove undigested tissue.
  • the cell suspension was washed 3 times with isolation buffer supplemented with trypsin inhibitor (0.75 mg/ml, Worthington #2829) and finally resuspended in culture medium; DMEM (Gibco 041-01965) supplemented with 25 mM HEPES (Sigma H-3375), 4 mM glutamine (Gibco 043-05030H), 0.075% sodium bicarbonate (Sigma S-8875), 0.1% non-essential amino acid, 2.5% fetal calf serum (FCS, Gibco 011-06290), 3% horse serum (Gibco 034-06050), 10% fresh rat serum, 1 nM T 3 (Sigma T-2752) and 40 mg/L dexamethasone (Sigma D-4902) pH 7.3, to a density of 2 ⁇ 10 5 cells/ml.
  • the cells were seeded into microtiter plates (Nunc, Denmark), 200 ml/well, and cultured for 3 days at 37°C and 8% CO 2 .
  • the cells were washed twice with stimulation buffer (Hanks Balanced Salt Solution (Gibco 041-04020) supplemented with 1% BSA (Sigma A-4503), 0.25% D-glucose (Sigma G-5250) and 25 mM HEPES (Sigma H-3375) pH 7.3) and preincubated for 1 hour at 37°C.
  • the buffer was exchanged with 90 ml stimulation buffer (37°C).
  • Ten ml test compound solution was added and the plates were incubated for 15 min at 37oC and 5% CO 2 .
  • the medium was decanted and analyzed for GH content in an rGH SPA test system.
  • Standard peptides (angiotensin 1-14, ACTH 4-10 and glucagon) were purchased from Sigma, MO, USA)
  • Enzymes (trypsin, chymotrypsin, elastase aminopeptidase M and carboxypeptidase Y and B) were all purchased from Boehringer Mannheim GmbH (Mannheim, Germany)
  • Pancreatic enzyme mix trypsin, chymotrypsin and elastase in 100 mM ammoniumbicarbonate pH 8.0 (all concentrations 0.025 mg/ml).
  • Carboxypeptidase mix carboxypeptidase Y and B in 50 mM ammoniumacetate pH 4.5 (all concentrations 0.025 mg/ml).
  • Aminopeptidase M solution aminopeptidase M (0.025 mg/ml) in 100 mM ammoniumbicarbonate pH 8.0
  • Mass spectrometric analysis was performed using two different mass spectrometers.
  • a Sciex API III triple quadrupole LC-MS instrument (Sciex instruments, Thornhill, Ontario) equipped with an electrospray ion-source and a Bio-Ion 20 time-of-flight Plasma Desorption instrument (Bio-Ion Nordic AB, Uppsala, Sweden).
  • Quantification of the compounds was done on the API III instrument using single ion monitoring of the molecular ion in question with flow injection of the analyte.
  • the liquid flow (MeOH:water 1:1) of 100 ml/min was controlled by an ABI 140B HPLC unit (Perkin-Elmer Applied Biosystems Divisions, Foster City, CA).
  • the instrument parameters were set to standard operation conditions, and SIM monitoring was performed using the most intense molecular ion (in most cases this corresponded to the doubly charged molecular ion).
  • Identification of degradation products furthermore involved the use of plasma desorption mass spectrometry (PDMS) with sample application on nitrocellulose coated targets and standard instrumental settings.
  • PDMS plasma desorption mass spectrometry
  • the accuracy of the hereby determined masses is generally better than 0.1%.
  • TLC thin layer chromatography and THF is tetrahydrofuran, CDCl 3 is deuterio chloroform, DMSO-d 6 is hexadeuterio dimethylsulfoxide and CD 3 OD is tetradeuterio methanol.
  • the structure of the compounds are confirmed by either elemental analysis or NMR, where peaks assigned to characteristic protons in the title compounds are presented where appropriate.
  • 1 H NMR shift (d H ) are given in parts per million (ppm).
  • M.p. melting point and is given in °C and is not corrected. Column chromatography was carried out using the technique described by W.C. Still et al., J. Org. Chem.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des nouveaux composés de formule générale (I), qui favorisent la libération de l'hormone de croissance chez les humains et les animaux. Cette propriété peut être utilisée pour favoriser la croissance d'animaux destinés à l'alimentation, rendre la production de produits carnés comestibles plus efficace, et, chez les humains, améliorer l'état de ceux souffrant d'une sécrétion insuffisante de l'hormone de croissance naturelle. L'invention porte aussi sur des compositions favorisant la croissance, dont le principe actif est constitué desdits composés de formule I, sur des procédés de stimulation de la libération de l'hormone de croissance ainsi que sur l'utilisation des composés de formule I.
PCT/DK1996/000059 1995-02-09 1996-02-06 Compose favorisant la liberation de l'hormone de croissance WO1996024587A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU45346/96A AU4534696A (en) 1995-02-09 1996-02-06 Compounds with growth hormone releasing properties

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK0147/95 1995-02-09
DK14795 1995-02-09

Publications (1)

Publication Number Publication Date
WO1996024587A1 true WO1996024587A1 (fr) 1996-08-15

Family

ID=8090300

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK1996/000059 WO1996024587A1 (fr) 1995-02-09 1996-02-06 Compose favorisant la liberation de l'hormone de croissance

Country Status (4)

Country Link
AU (1) AU4534696A (fr)
IL (1) IL117076A0 (fr)
WO (1) WO1996024587A1 (fr)
ZA (1) ZA961008B (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107306A (en) * 1995-12-28 2000-08-22 Pfizer Inc. Heterocyclic compounds
EP1159964A2 (fr) 2000-05-31 2001-12-05 Pfizer Products Inc. Compositions et methodes pour stimuler la motilité gastrointestinale
US6605623B1 (en) 1998-12-18 2003-08-12 Bristol-Myers Squibb Pharma Co. N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
WO2007098716A1 (fr) 2006-02-28 2007-09-07 Centro De Ingeniería Genética Y Biotecnología Composés analogues aux sécrétagogues peptidiques de l'hormone de croissance et préparations contenant ceux-ci
EP1930021A2 (fr) 1999-02-18 2008-06-11 Kaken Pharmaceutical Co., Ltd. Nouveaux dérivés d'amide en tant que secrétagogues d'hormone de croissance
EP2457893A1 (fr) 2004-06-18 2012-05-30 Tranzyme Pharma, Inc. Intermédiaires pour des modulateurs macrocycliques du récepteur de ghréline
EP2644618A1 (fr) 2007-02-09 2013-10-02 Tranzyme Pharma, Inc. Intermédaires dans la synthese de modulateurs macrocycliques du récepteur de la ghréline
WO2013190520A2 (fr) 2012-06-22 2013-12-27 The General Hospital Corporation Agents de libération de gh dans le traitement d'une sténose vasculaire et d'états associés
US9302989B2 (en) 2010-11-15 2016-04-05 Abbvie Inc. NAMPT and rock inhibitors
WO2017075535A1 (fr) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Méthodes de traitement de troubles neurodégénératifs
US10105416B2 (en) 2014-02-05 2018-10-23 The Regents Of The University Of California Methods of treating mild brain injury

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No relevant documents have been disclosed. *

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6110932A (en) * 1995-12-28 2000-08-29 Pfizer Inc. Growth hormone secretagogues
US6124264A (en) * 1995-12-28 2000-09-26 Pfizer Inc. Heterocyclic compounds
US6278000B1 (en) 1995-12-28 2001-08-21 Pfizer Inc. Growth-hormone secretagogues
US6306875B1 (en) 1995-12-28 2001-10-23 Pfizer Inc. Growth-hormone secretagogues
US6313140B1 (en) 1995-12-28 2001-11-06 Pfizer Inc. Method of treatment using certain growth-hormone secret agogues
US6482825B2 (en) 1995-12-28 2002-11-19 Pfizer Inc. Growth-hormone secretagogues
US6107306A (en) * 1995-12-28 2000-08-22 Pfizer Inc. Heterocyclic compounds
US6605623B1 (en) 1998-12-18 2003-08-12 Bristol-Myers Squibb Pharma Co. N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6906066B2 (en) 1998-12-18 2005-06-14 Bristol-Myers Squibb Pharma Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
EP1930021A2 (fr) 1999-02-18 2008-06-11 Kaken Pharmaceutical Co., Ltd. Nouveaux dérivés d'amide en tant que secrétagogues d'hormone de croissance
EP1159964A2 (fr) 2000-05-31 2001-12-05 Pfizer Products Inc. Compositions et methodes pour stimuler la motilité gastrointestinale
EP2457893A1 (fr) 2004-06-18 2012-05-30 Tranzyme Pharma, Inc. Intermédiaires pour des modulateurs macrocycliques du récepteur de ghréline
WO2007098716A1 (fr) 2006-02-28 2007-09-07 Centro De Ingeniería Genética Y Biotecnología Composés analogues aux sécrétagogues peptidiques de l'hormone de croissance et préparations contenant ceux-ci
EP2644618A1 (fr) 2007-02-09 2013-10-02 Tranzyme Pharma, Inc. Intermédaires dans la synthese de modulateurs macrocycliques du récepteur de la ghréline
US9302989B2 (en) 2010-11-15 2016-04-05 Abbvie Inc. NAMPT and rock inhibitors
US10093624B2 (en) 2010-11-15 2018-10-09 Abbvie Inc. NAMPT and ROCK inhibitors
WO2013190520A2 (fr) 2012-06-22 2013-12-27 The General Hospital Corporation Agents de libération de gh dans le traitement d'une sténose vasculaire et d'états associés
US10105416B2 (en) 2014-02-05 2018-10-23 The Regents Of The University Of California Methods of treating mild brain injury
US10617740B2 (en) 2014-02-05 2020-04-14 The Regents Of The University Of California Methods of treating mild brain injury
US11241483B2 (en) 2014-02-05 2022-02-08 The Regents Of The University Of California Methods of treating mild brain injury
WO2017075535A1 (fr) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Méthodes de traitement de troubles neurodégénératifs

Also Published As

Publication number Publication date
IL117076A0 (en) 1996-06-18
ZA961008B (en) 1996-08-29
AU4534696A (en) 1996-08-27

Similar Documents

Publication Publication Date Title
EP1184370B1 (fr) Composés ayant des propriétés de libération de l'hormone de croissance
EP0869974B1 (fr) Composes avec des proprietes de liberation de l'hormone de croissance
ES2331102T3 (es) Compuestos con propiedades de liberacion de la hormona del crecimiento.
US6576648B2 (en) Compound with growth hormone releasing properties
WO1997000894A1 (fr) Composes presentant des proprietes de liberation de l'hormone de croissance
US6303620B1 (en) Compounds with growth hormone releasing properties
EP0907643B1 (fr) Composes capables de liberer une hormone de croissance
WO1996024580A1 (fr) Composes favorisant la liberation de l'hormone de croissance
US6127341A (en) Compounds with growth hormone releasing properties
WO1996024587A1 (fr) Compose favorisant la liberation de l'hormone de croissance
WO1998058950A1 (fr) Composes ayant des proprietes de liberation de l'hormone de croissance
US5919777A (en) Compounds with growth hormone releasing properties
JP2002519436A (ja) 成長ホルモン放出特性を有する化合物
US6566337B1 (en) Compounds with growth hormone releasing properties
JP2002509156A (ja) 成長ホルモン放出特性を有する化合物
EP1127071B1 (fr) Composes presentant des proprietes de liberation d'hormone de croissance
IL149049A (en) 2 - amino - n - [(1r) - 2 - [(3r) - 3 benzyl - 3 - (benzyl - 3 - (n', n', n - trimethylhydrazinocarbonyl) piperidin - 1 - yl] - 1 - (1h - indol - 3 - ylmethyl) - 2 oxoethyl] - 2 - methylpropionamide, pharmaceutical composition comprising it and its use for the manufacturing of medicaments for releasing growth hormone

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AZ BY KG KZ RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase